Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ROBERTSON, STEPHENS MEDICAL CONFERENCE HIGHLIGHTS: Coram

Executive Summary

Coram: Reduction of work force by 250 full-time equivalents concluded on Nov. 30, Coram's new President and CEO Donald Amaral reports Nov. 30. An additional reduction of 115 FTEs is to be completed March 30. The number of Coram home health care branches has been cut back from 318 to 130. Amaral will focus on reducing operation costs and consolidating the six former companies of which Coram is comprised. The company recently restructured the major terms of its debt and was given a new $25 mil. credit line with Chemical Bank. Amaral started at Coram on Oct. 16. He was previously president and chief operating officer at OrNda Healthcorp...

Coram: Reduction of work force by 250 full-time equivalents concluded on Nov. 30, Coram's new President and CEO Donald Amaral reports Nov. 30. An additional reduction of 115 FTEs is to be completed March 30. The number of Coram home health care branches has been cut back from 318 to 130. Amaral will focus on reducing operation costs and consolidating the six former companies of which Coram is comprised. The company recently restructured the major terms of its debt and was given a new $25 mil. credit line with Chemical Bank. Amaral started at Coram on Oct. 16. He was previously president and chief operating officer at OrNda Healthcorp....

Latest Headlines
See All
UsernamePublicRestriction

Register

PS027333

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel